Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system

Shaobo Zhang, Guangyuan Zeng, Chinghai Kao, Thomas Gardner, Christopher Sweeney, Ning Sun Yang, John Eble, Liang Cheng

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND. Recent data suggest that anti-tumor activities of interleukin-12 (IL-12) involve the induction of apoptosis. Fas (APO-1/CD95) is a type I membrane protein that is capable of initiating an apoptosis signaling pathway when bound to its ligand (FasL). We undertook this study to test the hypothesis that Fas-FasL -mediated apoptosis plays a role in IL-12-induced tumor regression. METHODS. An mIL-12 expression vector driven by cytomegalovirus promoter was used to express murine IL-12 cDNA in the RM-9 murine prostate carcinoma cell line. Control RM-9 cells and RM-9 cells stably transfected with IL-12 gene (RM-9-IL12) were inoculated subcutaneously in 4- to 6-week-old male C57BL/J6 mice. Tumor size was measured every 3 days. Western blot and immunohistochemical assays were used to evaluate Fas and FasL protein expression. In situ fluorescent end labeling was used to label apoptotic cells. RESULTS. IL-12-expressing RM-9 prostate carcinoma cells transplanted into C57BL/J6 mice grew more slowly than control RM-9 cells and vector control RM-9-Luc cells. The average survival time of the RM-9-IL12 mice was longer than 53 days, whereas the mean survival for mice transplanted with control RM-9 cells was only 16 days. Apoptotic cells were more numerous in RM-9-IL12 tumors: 10.3% vs. 1.5% in control (P = 0.001). Fas and FasL proteins were increased approximately twofold in the RM-9-IL12 tumors compared with the RM-9 control tumors as determined by Western blot and immunohistochemical analyses (P < 0.05). CONCLUSION. The Fas-FasL-mediated apoptosis pathway may contribute to the IL-12-induced rejection of prostate carcinoma.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalProstate
Volume53
Issue number1
DOIs
StatePublished - Sep 15 2002

Fingerprint

Fas Ligand Protein
Interleukin-12
Prostate
Neoplasms
Apoptosis
Carcinoma
Inbred C57BL Mouse
Western Blotting
Cytomegalovirus
Membrane Proteins
Complementary DNA
Ligands
Cell Line

Keywords

  • Apoptosis
  • Fas
  • Fas ligand
  • Interleukin-12
  • Prostate

ASJC Scopus subject areas

  • Urology

Cite this

Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. / Zhang, Shaobo; Zeng, Guangyuan; Kao, Chinghai; Gardner, Thomas; Sweeney, Christopher; Yang, Ning Sun; Eble, John; Cheng, Liang.

In: Prostate, Vol. 53, No. 1, 15.09.2002, p. 69-76.

Research output: Contribution to journalArticle

@article{4875b0af795a4e7ea7187b2a0db13e5b,
title = "Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system",
abstract = "BACKGROUND. Recent data suggest that anti-tumor activities of interleukin-12 (IL-12) involve the induction of apoptosis. Fas (APO-1/CD95) is a type I membrane protein that is capable of initiating an apoptosis signaling pathway when bound to its ligand (FasL). We undertook this study to test the hypothesis that Fas-FasL -mediated apoptosis plays a role in IL-12-induced tumor regression. METHODS. An mIL-12 expression vector driven by cytomegalovirus promoter was used to express murine IL-12 cDNA in the RM-9 murine prostate carcinoma cell line. Control RM-9 cells and RM-9 cells stably transfected with IL-12 gene (RM-9-IL12) were inoculated subcutaneously in 4- to 6-week-old male C57BL/J6 mice. Tumor size was measured every 3 days. Western blot and immunohistochemical assays were used to evaluate Fas and FasL protein expression. In situ fluorescent end labeling was used to label apoptotic cells. RESULTS. IL-12-expressing RM-9 prostate carcinoma cells transplanted into C57BL/J6 mice grew more slowly than control RM-9 cells and vector control RM-9-Luc cells. The average survival time of the RM-9-IL12 mice was longer than 53 days, whereas the mean survival for mice transplanted with control RM-9 cells was only 16 days. Apoptotic cells were more numerous in RM-9-IL12 tumors: 10.3{\%} vs. 1.5{\%} in control (P = 0.001). Fas and FasL proteins were increased approximately twofold in the RM-9-IL12 tumors compared with the RM-9 control tumors as determined by Western blot and immunohistochemical analyses (P < 0.05). CONCLUSION. The Fas-FasL-mediated apoptosis pathway may contribute to the IL-12-induced rejection of prostate carcinoma.",
keywords = "Apoptosis, Fas, Fas ligand, Interleukin-12, Prostate",
author = "Shaobo Zhang and Guangyuan Zeng and Chinghai Kao and Thomas Gardner and Christopher Sweeney and Yang, {Ning Sun} and John Eble and Liang Cheng",
year = "2002",
month = "9",
day = "15",
doi = "10.1002/pros.10132",
language = "English",
volume = "53",
pages = "69--76",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system

AU - Zhang, Shaobo

AU - Zeng, Guangyuan

AU - Kao, Chinghai

AU - Gardner, Thomas

AU - Sweeney, Christopher

AU - Yang, Ning Sun

AU - Eble, John

AU - Cheng, Liang

PY - 2002/9/15

Y1 - 2002/9/15

N2 - BACKGROUND. Recent data suggest that anti-tumor activities of interleukin-12 (IL-12) involve the induction of apoptosis. Fas (APO-1/CD95) is a type I membrane protein that is capable of initiating an apoptosis signaling pathway when bound to its ligand (FasL). We undertook this study to test the hypothesis that Fas-FasL -mediated apoptosis plays a role in IL-12-induced tumor regression. METHODS. An mIL-12 expression vector driven by cytomegalovirus promoter was used to express murine IL-12 cDNA in the RM-9 murine prostate carcinoma cell line. Control RM-9 cells and RM-9 cells stably transfected with IL-12 gene (RM-9-IL12) were inoculated subcutaneously in 4- to 6-week-old male C57BL/J6 mice. Tumor size was measured every 3 days. Western blot and immunohistochemical assays were used to evaluate Fas and FasL protein expression. In situ fluorescent end labeling was used to label apoptotic cells. RESULTS. IL-12-expressing RM-9 prostate carcinoma cells transplanted into C57BL/J6 mice grew more slowly than control RM-9 cells and vector control RM-9-Luc cells. The average survival time of the RM-9-IL12 mice was longer than 53 days, whereas the mean survival for mice transplanted with control RM-9 cells was only 16 days. Apoptotic cells were more numerous in RM-9-IL12 tumors: 10.3% vs. 1.5% in control (P = 0.001). Fas and FasL proteins were increased approximately twofold in the RM-9-IL12 tumors compared with the RM-9 control tumors as determined by Western blot and immunohistochemical analyses (P < 0.05). CONCLUSION. The Fas-FasL-mediated apoptosis pathway may contribute to the IL-12-induced rejection of prostate carcinoma.

AB - BACKGROUND. Recent data suggest that anti-tumor activities of interleukin-12 (IL-12) involve the induction of apoptosis. Fas (APO-1/CD95) is a type I membrane protein that is capable of initiating an apoptosis signaling pathway when bound to its ligand (FasL). We undertook this study to test the hypothesis that Fas-FasL -mediated apoptosis plays a role in IL-12-induced tumor regression. METHODS. An mIL-12 expression vector driven by cytomegalovirus promoter was used to express murine IL-12 cDNA in the RM-9 murine prostate carcinoma cell line. Control RM-9 cells and RM-9 cells stably transfected with IL-12 gene (RM-9-IL12) were inoculated subcutaneously in 4- to 6-week-old male C57BL/J6 mice. Tumor size was measured every 3 days. Western blot and immunohistochemical assays were used to evaluate Fas and FasL protein expression. In situ fluorescent end labeling was used to label apoptotic cells. RESULTS. IL-12-expressing RM-9 prostate carcinoma cells transplanted into C57BL/J6 mice grew more slowly than control RM-9 cells and vector control RM-9-Luc cells. The average survival time of the RM-9-IL12 mice was longer than 53 days, whereas the mean survival for mice transplanted with control RM-9 cells was only 16 days. Apoptotic cells were more numerous in RM-9-IL12 tumors: 10.3% vs. 1.5% in control (P = 0.001). Fas and FasL proteins were increased approximately twofold in the RM-9-IL12 tumors compared with the RM-9 control tumors as determined by Western blot and immunohistochemical analyses (P < 0.05). CONCLUSION. The Fas-FasL-mediated apoptosis pathway may contribute to the IL-12-induced rejection of prostate carcinoma.

KW - Apoptosis

KW - Fas

KW - Fas ligand

KW - Interleukin-12

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=0037106048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037106048&partnerID=8YFLogxK

U2 - 10.1002/pros.10132

DO - 10.1002/pros.10132

M3 - Article

C2 - 12210482

AN - SCOPUS:0037106048

VL - 53

SP - 69

EP - 76

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -